Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic

    AUSTIN, TX and TORONTO, March 4 /CNW/ - Affinium Pharmaceuticals today
announced that they have commenced the dosing of healthy subjects in a Phase I
study of AFN-1252, one of its lead clinical candidates from its novel class of
fatty acid biosyntheis inhibitors. The study of AFN-1252 will evaluate the
safety, tolerability and pharmacokinetics of a single escalating oral dose.
Affinium believes that AFN-1252 will provide patients and their doctors a
potent, oral and IV treatment for susceptible and resistant staphylococcal
infections both in and out of hospitals.
    AFN-1252 is an investigational antibiotic, with a novel mechanism of
action, and very high potency against all drug-resistant phenotpyes of
staphylococci including hospital and community-acquired MRSA. Oral
bioavailability has previously been demonstrated in a human microdosing study
and excellent in vivo efficacy has been demonstrated in various animal models
of infection.
    "Affinium is very pleased to advance this novel class of antibiotics with
great potential to address the serious unmet medical need for new oral and IV
antibiotics capable of treating multi-drug resistant staphylococcal
infections," said Dr. Barry Hafkin, Chief Medical Officer of Affinium
Pharmaceuticals. "In preclinical studies, AFN-1252 was well tolerated at high
multiples of the projected human dose in two species, suggesting a safety
profile that would be very attractive to physicians practicing both in and out
of hospital settings." Dr. Hafkin added that "the specific-spectrum of
activity of AFN-1252 may provide further safety advantages by decreasing the
risk of gut and cutaneous flora disruption."

    About Affinium Pharmaceuticals

    Affinium Pharmaceuticals is a specialty pharmaceutical company focused on
the discovery, development and commercialization of novel anti-infective
medicines. AFN-1252 utilizes a unique mechanism of action by directly
inhibiting the function of the bacterial fatty acid synthesis (FAS) II
pathway. Affinium's FASII antibacterial programs constitute a new antibiotic
franchise with the potential for multiple products targeting the FASII
pathway. These programs include a broad base of long-term intellectual
property: issued and pending composition of matter patents on potent orally
available small molecule inhibitors of a new class of antibiotics with a
unique mechanism of action, targeting an underexploited pathway and are not
subject to resistance selection pressures caused by the use of existing broad
spectrum antibiotics.

For further information:

For further information: Barry Hafkin, Chief Medical Officer, Affinium
Pharmaceuticals, (512) 514-6631,; Owen Roberts, Chief
Financial Officer, Affinium Pharmaceuticals, (416) 645-6613,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890